



The Orchestra Study

An Interview with Diego Morita, MD, Study Physician for the Orchestra Study

Davis Phinney Foundation

Melani Dizon (Director of Education, Davis Phinney Foundation):

Hi everyone and welcome. My name is Melani Dizon. I'm the director of education at the Davis Phinney Foundation. And today, I am excited to talk to Dr. Diego Morita. He's the study physician on the Orchestra Trial. And I know a lot of people in our community have heard about the Orchestra Study and we're excited to talk to him today about it. So, can you give us the rundown? What is the Orchestra Study?

Diego Morita, MD (Study Physician for the Orchestra Study):

Yes. Thank you, Mel. So, the Orchestra Study examines an investigation medication called UCB0599 in individuals with early-stage Parkinson's disease. And this study, we are trying to find out if the study drug, UCB0599, is able to slow down the progression of Parkinson's disease and, as a result, its symptoms as well. And in order to do this, participants in the study must have early-stage Parkinson's disease with mild symptoms and not yet require treatment to control symptoms.

Melani Dizon:

Okay, great. So how does the medication in the trial work?

Diego Morita:

Well in Parkinson's disease, there is an abnormal clumping of a protein called alpha-synuclein, which some researchers think are toxic. And this clumping of alpha-synuclein can lead to cell death and then cause cell death in nearby cells, leading to the symptoms of Parkinson's disease. The study drug UCB0599 prevents the abnormal clumping of alpha-synuclein and therefore has the potential to slow down the progression of Parkinson's disease.

Melani Dizon:

Okay. So what stage is this trial in and what is the focus of the stage of the trial? Diego Morita:

So, the Orchestra Study is a Phase 2 study in which up to several hundred people with the disease participate. And the main purpose of the Phase 2 study is to gather additional safety data to what was collected in Phase 1, and also get some data to support continued research. Our, the goals of the Phase 2 study are to refine research questions, develop research methods and use the data collected to design the studies for the next Phase of drug development.

Melani Dizon:

Okay. So why would somebody be living with Parkinson's or how would somebody be living with Parkinson's benefit from participating in the study?

Diego Morita:

Sure. So, the current state of treatment in Parkinson's disease is mainly symptomatic treatment, meaning that available treatments target symptoms of Parkinson's disease, primarily motor symptoms. However, despite the symptomatic treatment, Parkinson's disease, being a neurodegenerative disorder, continues to progress and worsen over time. So, I mentioned before the Orchestra Study is about a new medication called UCB0599, taken by mouth, that has the potential to protect brain cells affected by Parkinson's disease and therefore slow down the progression or worsening of the disease. Another advantage of participating in clinical study, like the Orchestra Study, is the frequent interaction with the doctor and treating team, including close monitoring of symptoms, which may be more frequent than in typical clinical care. And as in many clinical studies, some study participants will receive active drug in the form of a capsule and others will receive placebo, which in this study is a lookalike capsule without the active drug. In their case study, the chance of receiving the active drug UCB0599 is twice as high as the chances of receiving placebo. And in addition, all of the participants that complete the study have the option to participate in the long-term extension study in which all participants will receive the active drug UCB0599.

Melani Dizon:

Great. So, what are the logistics? I know people want to know about the intake, the metrics, the commitment location groups, all that kind of stuff.

Diego Morita:

So, the Orchestra Study lasts 21 months in total. The study will evaluate the safety and targetability of UCB0599 and whether it slows down symptoms of Parkinson's disease. This means that potential side effects will be recorded and evaluated. We will also take brain images to look at nerve cells, usually affected by the disease. In addition, we will record symptoms and see how the impact daily activities of type participants. Also, if the study participant agrees to this, certain symptoms will be additionally monitored with a special



wearable sensor. The Orchestra study is being conducted in multiple study centers in North America and Europe, and there will be approximately 450 participants contributing to the study. Overall participation in the Orchestra Study will include 13 visits at the clinic with the study doctor and the study team, and three additional visits that will have the option to be done at the participants' home.

Melani Dizon:

Great. So, who qualifies for this study?

Diego Morita:

Well, there are several criteria to meet in order to join the Orchestra Study, but important ones are being 40 to 75 years of age, have been diagnosed with Parkinson's disease within two years of entry into the study, experienced slowness of movement and muscle stiffness or rigidity and/or tremor or shaking and have only mild symptoms. They have not taken medications to treat symptoms of Parkinson's Disease and not been expected to need any such medication in the following six months. You know, there are a few exceptions for the previous treatment criterion, but this would be better discussed with the study team. So, there are other criteria that potentially the potential participants need to meet five for the study, but again, this would be better discussed with the study team.

Melani Dizon:

Okay, great. So how can people find out more particularly if they qualify and can take part in it? Diego Morita:

So, there is a study website where potential participants can read about the study and check if there is a study center. There is also a link to a pre-screening questionnaire to see if they may qualify and foundation will provide link. Also, participants can read about this study on Centerwatch and reach out to potential study sites near them via the Centerwatch Portal, which again, I believe the foundation will provide.

Melani Dizon:

Yeah. We'll absolutely share the links in the notes and in the video. So, thank you. That's great. We'll definitely send people your way. So, when do you think that results will be shared from this phase stage two study and when does the trial close?

Diego Morita:

Yeah, so the Orchestra Study is expected to be completed in mid 2024 and the results are



expected to be shared thereafter.

Melani Dizon:

Okay. That's great. Well, our community absolutely loves learning about trials, participating in trials. And so, I look forward to sharing this with everybody. I really appreciate you being here, Dr. Morita, and best of luck with this study.

Diego Morita:

Thank you again, Mel, for the opportunity to share information about this study to your constituents.

Melani Dizon:

Thank you.